

# Mackenzie US Small-Mid Cap Growth Currency Neutral Fund Series A

## US Equity

### Compound Annualized Returns<sup>†</sup> 12/31/2024

|                             |       |
|-----------------------------|-------|
| 1 Month                     | -6.6% |
| 3 Months                    | -6.3% |
| Year-to-date                | 0.7%  |
| 1 Year                      | 0.7%  |
| 2 Years                     | 4.1%  |
| 3 Years                     | -6.4% |
| 5 Years                     | 0.9%  |
| 10 Years                    | 5.0%  |
| Since inception (Mar. 2006) | 7.3%  |

### Regional Allocation 11/30/2024

|                               |      |
|-------------------------------|------|
| <b>CASH &amp; EQUIVALENTS</b> |      |
| Cash & Equivalents            | 2.0% |

|                |       |
|----------------|-------|
| <b>OVERALL</b> |       |
| United States  | 95.8% |
| Israel         | 2.2%  |


### Sector Allocation 11/30/2024

|                        |       |
|------------------------|-------|
| Health Care            | 33.6% |
| Information Technology | 28.4% |
| Industrials            | 22.9% |
| Real Estate            | 7.1%  |
| Consumer Staples       | 3.7%  |
| Financials             | 2.3%  |
| Cash & Equivalents     | 2.0%  |


### Portfolio Managers

**Mackenzie Growth Team**  
 Phil Taller, John Lumbers

### Calendar Year Returns (%) 12/31/2024



### Value of \$10,000 invested 12/31/2024



### Major Holdings\*\*\* 11/30/2024

Major Holdings Represent 45.2% of the fund

|  |      |
|--|------|
| CoStar Group Inc                             | 5.2% |
| Maximus Inc                                  | 4.9% |
| Akamai Technologies Inc                      | 4.8% |
| Bio-Techne Corp                              | 4.6% |
| iRhythm Technologies Inc                     | 4.4% |
| Verra Mobility Corp                          | 4.4% |
| Charles River Laboratories International Inc | 4.4% |
| HealthEquity Inc                             | 4.3% |
| ExlService Holdings Inc                      | 4.2% |
| Neogen Corp                                  | 4.0% |

TOTAL NUMBER OF EQUITY HOLDINGS: 34

### Fund Risk Measures (3 year) 12/31/2024

|                        |       |              |       |
|------------------------|-------|--------------|-------|
| Annual Std Dev         | 17.96 | Beta         | 0.77  |
| B'mark Annual Std Dev. | 22.06 | R-squared    | 0.89  |
|                        |       | Sharpe Ratio | -0.57 |
| Alpha                  | -8.13 |              |       |

Source: Mackenzie Investments

### Key Fund Data

Total Fund Assets: **\$251.8 million**

NAVPS (12/31/2024): **C\$27.23**

MER (as of Sep. 2024): **A: 2.54% F: 1.05%**

Management Fee: **A: 2.00% F: 0.80%**

Benchmark\*\*": **Russell 2500 (Hedged to CAD)**

Last Paid Distribution:

| SERIES | FREQUENCY | AMOUNT | DATE       |
|--------|-----------|--------|------------|
| A      | Annually  | 0.9185 | 12/24/2021 |
| F      | Annually  | 1.2342 | 12/24/2021 |
| T8     | Monthly   | 0.0605 | 12/13/2024 |
| PW     | Annually  | 0.4732 | 12/24/2021 |

### Fund Codes:

| SERIES (C\$) | PREFIX | FE   | BE * | LL3 * |
|--------------|--------|------|------|-------|
| A            | MFC    | 8593 | 8600 | 8599  |
| F            | MFC    | 8594 | —    | —     |
| T8           | MFC    | 8598 | 8602 | 8604  |
| PW           | MFC    | 8612 | —    | —     |

Additional fund series available at  
[mackenzieinvestments.com/fundcodes](http://mackenzieinvestments.com/fundcodes)

### Why Invest in this fund?

- Access mid-cap stocks that can offer a unique risk-return 'sweet spot' between fast-growing small businesses and mature large companies.
- Gain exposure to innovative, secular growth businesses offering robust return potential across market cycles.
- Active management seeking alpha through in-depth research in a sparsely covered small- and mid-cap equity universe.

### Risk Tolerance

|     |        |             |
|-----|--------|-------------|
| LOW | MEDIUM | <b>HIGH</b> |
|-----|--------|-------------|



\* Effective June 1, 2022, the redemption charge purchase option, and the low-load purchase option are no longer available for purchase, including those made through systematic purchase plans such as pre-authorized contribution plans. Switching from securities of a Mackenzie Fund previously purchased under the redemption charge or low-load purchase options to securities of another Mackenzie Fund, under the same purchase option, will continue to be available until such redemption schedules expire.

\*\* The Russell 2500 Index measures the performance of the small- to mid-cap segment of the U.S. equity universe. The Index is a subset of the Russell 3000 Index. It includes approximately 2,500 of the smallest securities based on a combination of their market capitalization and current index membership.

\*\*\* The major holdings of the Fund may, but do not necessarily, represent the largest holdings of the Fund. Rather, the major holdings are selected for their overall significance in evaluating the investment portfolio.

† Commissions, trailing commissions, management fees, and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns as of December 31, 2024 including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution, or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Standard deviation provides a measure of the variability of returns that have occurred relative to the average return. The higher the standard deviation, the greater is the range of returns that has been experienced. Standard deviation is commonly used as a measure of risk.